ARTICLE | Deals
Plus: Day One adds PTK7 ADC from MabCare, and updates from Sanofi-Belharra and more
By Gunjan Ohri, Data Content Analyst
June 25, 2024 1:14 AM UTC
The past seven days brought at least two deals that could be worth over $1 billion, with Roche gaining access to a RNA editing technology from Ascidian, and Day One adding an antibody-drug conjugate (ADC) from MabCare.
Roche (SIX:ROG; OTCQX:RHHBY) paid $42 million up front to use Ascidian Therapeutics Inc.’s RNA exon editing platform to create therapies against undisclosed neurological disease targets. Ascidian’s technology enables correction of disease-causing mutations via pre-mRNA trans-splicing, which promises durable results while avoiding the risks of permanently altering the DNA via conventional gene editing. Ascidian, which is eligible for up to $1.8 billion in milestones, will conduct discovery and certain preclinical activities with Roche, after which the pharma will take over…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652796/deals-report-roche-licenses-ascidian-s-rna-editing-tech-for-neuro